Talecris joins crowd of stock offerings

tool name

tool name

Talecris set to go public

Talecris Biotherapeutics is expected to go public tonight, marking the first Wall Street debut for a Triangle company in more than two years.

The Research Triangle Park company makes medicines from blood plasma at a massive manufacturing plant in Clayton. Talecris was created in 2005 when two investment firms bought Bayer's blood-plasma business.

The IPO will enrich those firms, Talecris executives and some of its more than 2,000 local employees. The company employs more than 4,700 worldwide.

Talecris moving ahead with massive IPO

Talecris Biotherapeutics is preparing to move ahead with one of the largest initial public offerings of stock ever by a Triangle company.

The biotechnology company plans to sell 44.7 million shares at $18 to $20 each, according to a regulatory filing submitted late Thursday. At those terms, which could change before the final deal, the company would raise as much as $894 million before expenses.

By filing those details with the Securities and Exchange Commission, Talecris is taking is a crucial step to revive its long-delayed IPO. Company officials still must convince big Wall Street investors to buy its shares and receive SEC approval for the deal.

Talecris giving Wall Street another try

A biotechnology company is dusting off plans for what would be one of the Triangle's biggest Wall Street debuts.

Talecris Biotherapeutics first filed for an initial public offering of stock in June 2007, but scrapped the proposed IPO last summer when an Australian company agreed to buy it for $3.1 billion. Last month, the companies called off their union when the deal ran into trouble with U.S. antitrust regulators.

Talecris has since filed two updated registration documents with the U.S. Securities and Exchange Commission, a move that signals the Research Triangle Park company still harbors IPO dreams.

Talecris still mulling big IPO

A biotechnology company is dusting off plans for what would be one of the Triangle's biggest Wall Street debuts.

Talecris Biotherapeutics first filed for an initial public offering of stock in June 2007, but scrapped that when an Australian company last summer agreed to buy it for $3.1 billion. Then the acquisition ran into trouble with U.S. antitrust regulators and was called off last month.

Talecris has since started filing updated regulatory documents with the Securities and Exchange Commission, a move that signals the Research Triangle Park company still harbors IPO dreams.

Talecris execs set to talk up IPO

Officials with Talecris Biotherapeutics are hitting the road.

The Research Triangle Park company and the two investment firms that own it filed last week to raise up to $894 million in an initial public offering of stock. This week, they started the "road show," a couple of weeks during which company leaders sell the IPO to big money managers on Wall Street, such as pension funds and mutual funds.

Assuming they find a warm reception, Talecris is scheduled to go public Sept. 30, according to Renaissance Capital, a Greenwich, Conn., IPO research firm.